U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6337761

Indenolol hydrochloride is a mixture of 1-(7-in-denyloxy)-3-isopropylamino-2-propanol monohydrochloride and 1-(4-indenyloxy)-3-isopr opylamino-2-propanol monohydrochloride. Indenolol is a non-cardioselective beta blocker used to treat hypertension.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Blocker
555
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
PULSAN

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
22.97 ng/mL
CLINICAL TRIAL
https://doi.org/10.1002/j.1552-4604.1985.tb02851.x
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
INDENOLOL HYDROCHLORIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
22.99 ng/mL
CLINICAL TRIAL
https://doi.org/10.1002/j.1552-4604.1985.tb02851.x
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
INDENOLOL HYDROCHLORIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
31.54 ng/mL
CLINICAL TRIAL
https://doi.org/10.1002/j.1552-4604.1985.tb02851.x
120 mg 1 times / day multiple, oral
dose: 120 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
INDENOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
39.56 ng/mL
CLINICAL TRIAL
https://doi.org/10.1002/j.1552-4604.1985.tb02851.x
120 mg 1 times / day multiple, oral
dose: 120 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
INDENOLOL HYDROCHLORIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
191.59 ng × h/mL
CLINICAL TRIAL
https://doi.org/10.1002/j.1552-4604.1985.tb02851.x
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
INDENOLOL HYDROCHLORIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
174.68 ng × h/mL
CLINICAL TRIAL
https://doi.org/10.1002/j.1552-4604.1985.tb02851.x
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
INDENOLOL HYDROCHLORIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
303.44 ng × h/mL
CLINICAL TRIAL
https://doi.org/10.1002/j.1552-4604.1985.tb02851.x
120 mg 1 times / day multiple, oral
dose: 120 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
INDENOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
363.48 ng × h/mL
CLINICAL TRIAL
https://doi.org/10.1002/j.1552-4604.1985.tb02851.x
120 mg 1 times / day multiple, oral
dose: 120 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
INDENOLOL HYDROCHLORIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.06 h
CLINICAL TRIAL
https://doi.org/10.1002/j.1552-4604.1985.tb02851.x
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
INDENOLOL HYDROCHLORIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.55 h
CLINICAL TRIAL
https://doi.org/10.1002/j.1552-4604.1985.tb02851.x
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
INDENOLOL HYDROCHLORIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.65 h
CLINICAL TRIAL
https://doi.org/10.1002/j.1552-4604.1985.tb02851.x
120 mg 1 times / day multiple, oral
dose: 120 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
INDENOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.76 h
CLINICAL TRIAL
https://doi.org/10.1002/j.1552-4604.1985.tb02851.x
120 mg 1 times / day multiple, oral
dose: 120 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
INDENOLOL HYDROCHLORIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
320 mg 1 times / day multiple, oral
Highest studied dose
Dose: 320 mg, 1 times / day
Route: oral
Route: multiple
Dose: 320 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6110504/
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/6110504/
Sources:
https://pubmed.ncbi.nlm.nih.gov/6110504/
PubMed

PubMed

TitleDatePubMed
Indenolol: a new antihypertensive agent: efficacy, toxicity, and hemodynamic effects in a crossover double-blind study with metoprolol.
1985-07-01
Indenolol in hypertension.
1983-03
[Synthesis of new indene derivatives with -adrenergic blocking properties].
1972-11
Patents

Patents

BE 641417
1
DE 1955229
1

Sample Use Guides

In Vivo Use Guide
In clinical trials against hypertension, indenolol was administered daily at doses of 60 mg or 120 mg.
Route of Administration: Oral
In Vitro Use Guide
Indenolol hydrochloride exhibited beta-blocking activity in isolated atria with pA2 of 8.38.
Substance Class Mixture
Created
by admin
on Mon Mar 31 18:49:20 GMT 2025
Edited
by admin
on Mon Mar 31 18:49:20 GMT 2025
Record UNII
2VLW0IV0ZQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
INDENOLOL HYDROCHLORIDE [MI]
Preferred Name English
INDENOLOL HYDROCHLORIDE
MART.   MI   WHO-DD  
Common Name English
INDENOLOL HYDROCHLORIDE [JAN]
Common Name English
INDENOLOL HYDROCHLORIDE [MART.]
Common Name English
INDENOLOL HCL
Common Name English
Indenolol hydrochloride [WHO-DD]
Common Name English
Code System Code Type Description
CAS
81789-85-7
Created by admin on Mon Mar 31 18:49:20 GMT 2025 , Edited by admin on Mon Mar 31 18:49:20 GMT 2025
PRIMARY
EPA CompTox
DTXSID00988612
Created by admin on Mon Mar 31 18:49:20 GMT 2025 , Edited by admin on Mon Mar 31 18:49:20 GMT 2025
PRIMARY
FDA UNII
2VLW0IV0ZQ
Created by admin on Mon Mar 31 18:49:20 GMT 2025 , Edited by admin on Mon Mar 31 18:49:20 GMT 2025
PRIMARY
EVMPD
SUB02664MIG
Created by admin on Mon Mar 31 18:49:20 GMT 2025 , Edited by admin on Mon Mar 31 18:49:20 GMT 2025
PRIMARY
CAS
68906-88-7
Created by admin on Mon Mar 31 18:49:20 GMT 2025 , Edited by admin on Mon Mar 31 18:49:20 GMT 2025
SUPERSEDED
ChEMBL
CHEMBL153585
Created by admin on Mon Mar 31 18:49:20 GMT 2025 , Edited by admin on Mon Mar 31 18:49:20 GMT 2025
PRIMARY
MERCK INDEX
m6249
Created by admin on Mon Mar 31 18:49:20 GMT 2025 , Edited by admin on Mon Mar 31 18:49:20 GMT 2025
PRIMARY Merck Index
SMS_ID
100000086963
Created by admin on Mon Mar 31 18:49:20 GMT 2025 , Edited by admin on Mon Mar 31 18:49:20 GMT 2025
PRIMARY
All of the following components must be present:
Structure of 4-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)INDENE HYDROCHLORIDE
Structure of 7-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)INDENE HYDROCHLORIDE
Definition References
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966